Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.57 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.57 |
| ▸ | ACE | P12821 | 1/20 | 0.55 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.53 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.52 |
| ▸ | PPARA | Q07869 | 7/20 | 0.50 |
| ▸ | PPARG | P37231 | 6/20 | 0.50 |
| ▸ | CTSS | P25774 | 6/20 | 0.49 |
| ▸ | CTSK | P43235 | 5/20 | 0.49 |
| ▸ | PPARD | Q03181 | 2/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12241482 | 1.00 | ITGB3 (0.57) | ITGB3ITGA2BACEITGA4ITGB7 | |
| SCHEMBL33526968 | 0.89 | KLK5 (0.50) | ITGB3ITGA2BACEITGA4ITGB7 | |
| SCHEMBL12241473 | 0.89 | KLK5 (0.50) | ITGB3ITGA2BACEITGA4ITGB7 | |
| SCHEMBL27041520 | 0.86 | ITGB3 (0.56) | ITGB3ITGA2BACEITGA4ITGB7 | |
| SCHEMBL27041522 | 0.86 | ITGB3 (0.56) | ITGB3ITGA2BACEITGA4ITGB7 | |
| SCHEMBL2072417 | 0.86 | ITGB3 (0.56) | ITGB3ITGA2BACEITGA4ITGB7 | |
| SCHEMBL2072419 | 0.86 | ITGB3 (0.56) | ITGB3ITGA2BACEITGA4ITGB7 | |
| SCHEMBL8025768 | 0.86 | ITGB3 (0.56) | ITGB3ITGA2BACEITGA4ITGB7 | |
| SCHEMBL16644977 | 0.86 | ITGB3 (0.56) | ITGB3ITGA2BACEITGA4ITGB7 | |
| SCHEMBL31407738 | 0.85 | ITGA4 (0.56) | ITGB3ITGA2BACEITGA4ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | GIPR, GLP1R, GPR119 | ITGB3 1087/4885ITGA2B 1892/4885ACE 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.